Literature DB >> 14612556

p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.

Jane C Schroeder1, Kathleen Conway, Yu Li, Kusum Mistry, Douglas A Bell, Jack A Taylor.   

Abstract

Bladder cancer is associated with smoking, occupational exposures, and glutathione S-transferase (GST) M1 and N-acetyltransferase (NAT) 2 polymorphisms that may influence carcinogen metabolism, but somatic p53mutations are often CpG dinucleotide G:C-A:T transitions that can occur spontaneously. We conducted a case-control study to determine whether p53mutation characteristics might distinguish cases with environmental versus endogenous causes. p53exons 4-9 were amplified from 146 bladder tumors by PCR, screened by single-strand conformational polymorphism analysis, and sequenced. Thirty-one cases were p53-positive, and 112 were p53-negative (germ line or silent). G:C-A:T transitions were also subclassified as CpG or non-CpG. Cases and 215 clinic controls were interviewed. GSTM1, NAT1, and NAT2 polymorphisms were assayed from peripheral blood. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic and polytomous regression. Case-control ORs for smoking, occupations, and NAT1*10genotype were similar for p53-positive and p53-negative cases. Associations with GSTM1-null and NAT2-slow genotypes were somewhat stronger for p53-positive [OR, 3.3; CI, 1.4-7.8 (GSTM1 null); OR, 1.8; CI, 0.8-4.0 (NAT2 slow)] than p53-negative cases [OR, 1.5; CI:0.9-2.3 (GSTM1 null); OR, 0.9; CI, 0.6-1.4 (NAT2 slow)]. Smoking was strongly associated with CpG G:C-A:T (OR, 15.3; CI:3.6-65) versus other G:C-A:T (OR, 1.8; CI, 0.3-9.8). NAT2 slow genotypes were also associated with CpG G:C-A:T (OR, 6.2; CI:0.7-52), whereas GSTM1 null was associated with non-CpG G:C-A:T (OR, 7.8; CI, 0.9-65). Associations were not substantially different for case subtypes defined by p53mutation status alone. Estimates for p53 subtypes were imprecise but support in vitro evidence that some CpG G:C-A:T transitions may be caused by smoking and other environmental mutagens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612556

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Genetic susceptibility of methylenetetrahydrofolate reductase (MTHFR) gene C677T, A1298C, and G1793A polymorphisms with risk for bladder transitional cell carcinoma in men.

Authors:  Mohammad Reza Safarinejad; Nayyer Shafiei; Shiva Safarinejad
Journal:  Med Oncol       Date:  2010-10-29       Impact factor: 3.064

2.  Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.

Authors:  Sanaa Eissa; Samir F Zohny; Abdel-Rahman N Zekri; Tarek Mostafa El-Zayat; Amany M Maher
Journal:  Med Oncol       Date:  2009-12-11       Impact factor: 3.064

3.  Identification of potential therapeutic targets in urothelial bladder carcinoma of Chinese population by targeted next-generation sequencing.

Authors:  Tao Wang; Zhengsheng Liu; Xuegang Wang; Peide Bai; Anran Sun; Zhiqiang Shao; Rongtuan Luo; Zhun Wu; Kaiyan Zhang; Wei Li; Wen Xiao; Bo Duan; Yongfeng Wang; Bin Chen; Jinchun Xing
Journal:  Cancer Biol Ther       Date:  2020-05-23       Impact factor: 4.742

4.  A comparison of the polytomous logistic regression and joint cox proportional hazards models for evaluating multiple disease subtypes in prospective cohort studies.

Authors:  Xiaonan Xue; Mimi Y Kim; Mia M Gaudet; Yikyung Park; Moonseong Heo; Albert R Hollenbeck; Howard D Strickler; Marc J Gunter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-04       Impact factor: 4.254

5.  The structural location of DNA lesions in nucleosome core particles determines accessibility by base excision repair enzymes.

Authors:  Yesenia Rodriguez; Michael J Smerdon
Journal:  J Biol Chem       Date:  2013-03-29       Impact factor: 5.157

6.  Smoking status, usual adult occupation, and risk of recurrent urothelial bladder carcinoma: data from The Cancer Genome Atlas (TCGA) Project.

Authors:  Amber N Wilcox; Debra T Silverman; Melissa C Friesen; Sarah J Locke; Daniel E Russ; Noorie Hyun; Joanne S Colt; Jonine D Figueroa; Nathaniel Rothman; Lee E Moore; Stella Koutros
Journal:  Cancer Causes Control       Date:  2016-11-01       Impact factor: 2.506

7.  Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk.

Authors:  Weimin Gao; Marjorie Romkes; Shilong Zhong; Tomoko Nukui; Raj A Persad; Patrick J B Smith; Robert Branch; Phouthone Keohavong
Journal:  Oncol Rep       Date:  2010-07       Impact factor: 3.906

8.  NAT1 polymorphisms and cancer risk: a systematic review and meta-analysis.

Authors:  Kunyi Zhang; Lijuan Gao; Yuqi Wu; Jianyi Chen; Chengguang Lin; Shaohua Liang; Jianxin Su; Jinming Ye; Xuyu He
Journal:  Int J Clin Exp Med       Date:  2015-06-15

9.  TP53 genetic alterations in Arab breast cancer patients: Novel mutations, pattern and distribution.

Authors:  Abeer J Al-Qasem; Mohamed Toulimat; Abdelmoneim M Eldali; Asma Tulbah; Nujoud Al-Yousef; Sooad K Al-Daihan; Nada Al-Tassan; Taher Al-Tweigeri; Abdelilah Aboussekhra
Journal:  Oncol Lett       Date:  2011-01-18       Impact factor: 2.967

10.  Associations between polycyclic aromatic hydrocarbon-related exposures and p53 mutations in breast tumors.

Authors:  Irina Mordukhovich; Pavel Rossner; Mary Beth Terry; Regina Santella; Yu-Jing Zhang; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Mia M Gaudet; Susan E Steck; Sharon K Sagiv; Sybil M Eng; Susan L Teitelbaum; Alfred I Neugut; Kathleen Conway-Dorsey; Marilie D Gammon
Journal:  Environ Health Perspect       Date:  2009-11-18       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.